Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan A Burger

Showing results (151-160 of 223) with videos related to

Pageof 23
Sort By:
Blood|December 2, 2017
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignanciesIan W Flinn, Susan O'Brien, Brad Kahl, et al.
Plos One|December 31, 2013
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cellsStefania Fiorcari, Wells S Brown, Bradley W McIntyre, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 20, 2022
STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia CellsUri Rozovski, Ivo Veletic, David M Harris, et al.
Leukemia|October 9, 2021
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequencesAnneke D van Dijk, Ti'ara L Griffen, Yihua H Qiu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 StudyJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Blood Advances|May 12, 2019
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLLPaolo Strati, Koichi Takahashi, Christine B Peterson, et al.
Mediterranean Journal of Hematology and Infectious Diseases|July 17, 2020
Successful Outcomes of Severe COVID-19 in Patient with Chronic Lymphocytic Leukemia: Diagnostic Challenges in Immunocompromised HostsAlexandre E Malek, Cristina Gutierrez, Victor E Mulanovich, et al.
Blood|December 1, 2010
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemiaMariela Sivina, Elena Hartmann, Thomas J Kipps, et al.
Blood|September 19, 2009
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistanceAntonina V Kurtova, Kumudha Balakrishnan, Rong Chen, et al.
Haematologica|July 29, 2017
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemiaElisa ten Hacken, Maria Gounari, Jaap Willem Back, et al.
Pageof 23

Showing results (151-160 of 223) with videos related to

Sort By:
Pageof 23
Blood|December 2, 2017
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignanciesIan W Flinn, Susan O'Brien, Brad Kahl, et al.
Plos One|December 31, 2013
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cellsStefania Fiorcari, Wells S Brown, Bradley W McIntyre, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 20, 2022
STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia CellsUri Rozovski, Ivo Veletic, David M Harris, et al.
Leukemia|October 9, 2021
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequencesAnneke D van Dijk, Ti'ara L Griffen, Yihua H Qiu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 StudyJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Blood Advances|May 12, 2019
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLLPaolo Strati, Koichi Takahashi, Christine B Peterson, et al.
Mediterranean Journal of Hematology and Infectious Diseases|July 17, 2020
Successful Outcomes of Severe COVID-19 in Patient with Chronic Lymphocytic Leukemia: Diagnostic Challenges in Immunocompromised HostsAlexandre E Malek, Cristina Gutierrez, Victor E Mulanovich, et al.
Blood|December 1, 2010
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemiaMariela Sivina, Elena Hartmann, Thomas J Kipps, et al.
Blood|September 19, 2009
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistanceAntonina V Kurtova, Kumudha Balakrishnan, Rong Chen, et al.
Haematologica|July 29, 2017
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemiaElisa ten Hacken, Maria Gounari, Jaap Willem Back, et al.
Pageof 23